NCT02887859Phase 2Completed

Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2020-12Actual

Enrollment · participants15Actual

Source updated2025-04-18Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Peripheral Artery Disease

Treatments or interventions studied

Human Acellular Vessel (HAV)Biological

Primary outcomes · main study measures

Read the study measures

measure: Number of Participants With Aneurysm Formation, Anastomotic Bleeding or Spontaneous Rupture, HAV Infection, HAV Removal, and Significant Inflammation at the HAV Implantation Site; timeFrame: 12 months; measure: Number of Participants With Adverse Events; timeFrame: 12 months; measure: Number of Participants With HAV Patency Rates (Primary, Primary-assisted, Secondary); description: Primary patency = patent ("open" to blood flow) without any interventions; Primary-assisted patency = patent without an intervention to clear a thrombus; Secondary patency = patent with or without interventions; timeFrame: 12 months; measure: Number of Participants With Hemodynamically Significant Stenosis (>70% by Duplex Ultrasound Criteria); timeFrame: 12 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history